Abaloparatide 3mg
Abaloparatide
CAS: 247062-33-5
Abaloparatide is an FDA-approved synthetic analog of PTHrP(1-34) for osteoporosis. More anabolic and less catabolic than teriparatide (PTH analog) due to biased PTH1R agonism favoring the cAMP pathway over beta-arrestin internalization. 99.0% HPLC purity.
Specifications
For laboratory research use only. Not for human consumption.
Mechanism of Action
Biased PTH1R agonism: abaloparatide preferentially activates the G-protein/cAMP pathway over beta-arrestin recruitment. This RLA (R0) receptor conformation selectivity results in less osteoclast activation versus teriparatide while maintaining osteoblast stimulation.
Research FAQ
How does Abaloparatide compare to PTH (teriparatide)?
Abaloparatide shows preferential RLA conformation binding at PTH1R, producing stronger anabolic bone formation relative to catabolic resorption compared to teriparatide. Pivotal trials showed 28% greater spine BMD increase at 18 months vs teriparatide.
